These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 17532864)

  • 1. Naturalistic follow-up of co-morbid substance use in schizophrenia: the West London first-episode study.
    Harrison I; Joyce EM; Mutsatsa SH; Hutton SB; Huddy V; Kapasi M; Barnes TR
    Psychol Med; 2008 Jan; 38(1):79-88. PubMed ID: 17532864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anhedonia and social adaptation predict substance abuse evolution in dual diagnosis schizophrenia.
    Potvin S; Stip E; Lipp O; Roy MA; Demers MF; Bouchard RH; Gendron A
    Am J Drug Alcohol Abuse; 2008; 34(1):75-82. PubMed ID: 18161645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cannabis and schizophrenia: demographic and clinical correlates].
    Dervaux A; Laqueille X; Bourdel MC; Leborgne MH; Olié JP; Lôo H; Krebs MO
    Encephale; 2003; 29(1):11-7. PubMed ID: 12640322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders.
    Brunette MF; Noordsy DL; Xie H; Drake RE
    Psychiatr Serv; 2003 Oct; 54(10):1395-401. PubMed ID: 14557527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabis use and first-episode psychosis: relationship with manic and psychotic symptoms, and with age at presentation.
    Stone JM; Fisher HL; Major B; Chisholm B; Woolley J; Lawrence J; Rahaman N; Joyce J; Hinton M; Johnson S; Young AH;
    Psychol Med; 2014 Feb; 44(3):499-506. PubMed ID: 23701858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of comorbid substance use on neuropsychological performance in subjects with psychotic or mood disorders].
    Liraud F; Verdoux H
    Encephale; 2002; 28(2):160-8. PubMed ID: 11972143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychiatric comorbidity in first episode schizophrenia: a 2 year, longitudinal outcome study.
    Sim K; Chua TH; Chan YH; Mahendran R; Chong SA
    J Psychiatr Res; 2006 Oct; 40(7):656-63. PubMed ID: 16904688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders.
    Barrowclough C; Haddock G; Tarrier N; Lewis SW; Moring J; O'Brien R; Schofield N; McGovern J
    Am J Psychiatry; 2001 Oct; 158(10):1706-13. PubMed ID: 11579006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temperament and substance abuse in schizophrenia: is there a relationship?
    Van Ammers EC; Sellman JD; Mulder RT
    J Nerv Ment Dis; 1997 May; 185(5):283-8. PubMed ID: 9171804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of a first episode of psychosis in adolescence: a 2-year follow-up.
    Pencer A; Addington J; Addington D
    Psychiatry Res; 2005 Jan; 133(1):35-43. PubMed ID: 15698675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comorbid substance use and age at onset of schizophrenia.
    Barnes TR; Mutsatsa SH; Hutton SB; Watt HC; Joyce EM
    Br J Psychiatry; 2006 Mar; 188():237-42. PubMed ID: 16507965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationships between symptoms of schizophrenia and substance abuse.
    Brunette MF; Mueser KT; Xie H; Drake RE
    J Nerv Ment Dis; 1997 Jan; 185(1):13-20. PubMed ID: 9040528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Occurrence and clinical correlates of psychiatric comorbidity in patients with psychotic disorders.
    Cassano GB; Pini S; Saettoni M; Rucci P; Dell'Osso L
    J Clin Psychiatry; 1998 Feb; 59(2):60-8. PubMed ID: 9501887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The neuropsychology of cannabis and other substance use in schizophrenia: review of the literature and critical evaluation of methodological issues.
    Coulston CM; Perdices M; Tennant CC
    Aust N Z J Psychiatry; 2007 Nov; 41(11):869-84. PubMed ID: 17924240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabis and schizophrenia: results of a follow-up study.
    Caspari D
    Eur Arch Psychiatry Clin Neurosci; 1999; 249(1):45-9. PubMed ID: 10195343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conditional substance abuse and dependence by diagnosis of mood or anxiety disorder or schizophrenia in the U.S. population.
    Martins SS; Gorelick DA
    Drug Alcohol Depend; 2011 Dec; 119(1-2):28-36. PubMed ID: 21641123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Demographic and clinical correlates of substance use disorders in first episode psychosis.
    Brunette MF; Mueser KT; Babbin S; Meyer-Kalos P; Rosenheck R; Correll CU; Cather C; Robinson DG; Schooler NR; Penn DL; Addington J; Estroff SE; Gottlieb J; Glynn SM; Marcy P; Robinson J; Kane JM
    Schizophr Res; 2018 Apr; 194():4-12. PubMed ID: 28697856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective.
    Hambrecht M; Häfner H
    Aust N Z J Psychiatry; 2000 Jun; 34(3):468-75. PubMed ID: 10881971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization.
    Foti DJ; Kotov R; Guey LT; Bromet EJ
    Am J Psychiatry; 2010 Aug; 167(8):987-93. PubMed ID: 20478874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of substance abuse in schizophrenia: nature and significance.
    DeQuardo JR; Carpenter CF; Tandon R
    J Psychiatr Res; 1994; 28(3):267-75. PubMed ID: 7932286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.